Company Overview and News
Lennar Corp.'s LEN, +0.11% credit rating was upgraded Monday out of "junk" territory, following the completion of the deal in which the homebuilder acquired CalAtlantic Group Inc. in a $9.3 billion deal. The outlook was revised to stable. Fitch raised its rating to BBB-, the lowest investment grade rating, from BB+. The deal, which closed in February, and included $3.6 billion in assumed debt, created the largest homebuilder in terms of revenue and lifted the company into a top-3 position in 27 of the 30 largest metropolitan markets.
CAA LEN LEN.B
Lennar Corporation’s (LEN - Free Report) shares have been rallying since the second-quarter fiscal 2018 release on Jun 26, 2018. In fact, the nation’s largest homebuilder has outperformed the homebuilding industry so far this year. Although Lennar deteriorated 17% year to date, it fared better than the broader industry’s 19.7% decline. Recently, Lennar posted stellar second-quarter results, surpassing the Zacks Consensus Estimate on both counts.
CAA LEN DHI MDC LEN.B BZH BZMD
Lennar Corporation’s (LEN - Free Report) shares have gained 7.5% in pre-market trading, after surpassing earnings as well as revenue expectations in the second quarter of fiscal 2018 – the first full quarter with CalAtlantic. The company’s second-quarter adjusted earnings of $1.58 per share surpassed the Zacks Consensus Estimate of 45 cents. The reported figure mainly excludes integration costs related to the acquisition of CalAtlantic Group, Inc.
CAA MTH FFIV LEN MDC LEN.B BZH BZMD
Lennar Corporation (LEN - Free Report) is one of the leading homebuilders in the United States. With overall housing market recovering at a slow but steady pace, Lennar's order trends have been improving at a consistent pace. Lennar is performing well on the back of its diverse revenue mix, large land supply, above average order growth and better pricing power. Investors should also note that 2018 earnings estimate for LEN has remained stable in the past 60 days.
CAA EPC LEN LEN.B ZAGG
Lennar Corporation (LEN - Free Report) is scheduled to announce second-quarter fiscal 2018 results on Jun 26, before the opening bell. Lennar has been showcasing solid top-line performances and the trend is supposed to continue in the soon-to-be-reported quarter as well, courtesy of robust demand for homes, favorable job market and impressive economic conditions. Let’s take a look at how the company's margin is shaping up for this earnings season.
CAA MTH LEN HFC MDC LEN.B BZH BZMD
Chicago, IL – June 4, 2018 – Today, Zacks Equity Research discusses the Industry: Housing, Part 2, including Lennar (LEN - Free Report) , M/I Homes, Inc. (MHO - Free Report) and William Lyon Homes (WLH - Free Report) .
UA BRK.A NTLA CAA WCIC WLH WLS DB LEN UAA DG JBLU
Although the home sales data is not impressive so far this year, the larger picture is indeed a big success. Homebuilders still expect strong demand for new homes as low unemployment and steady economic growth support Americans’ buying power.
CCS WLH CAA WCIC MTH KBH WLS LEN MDC BZH BZMD
2018-05-27 investorplace - 1
Choppy trading this year has created buying opportunities in the market. After a 14-month bull run sent stocks of all kinds soaring, there have been a few stocks this year that have seen unwarranted sell-offs. Those “rebound stocks,” for lack of a better term, have been caught in market concerns about rising Treasury yields and a potential trade war, among other factors.
STZ.B NTRI WBA CVS GTN.A CAA GLSSP AMZN AMT VIAB AVGO ABLZF ED BGS MIK JBK GE TMUSP TMUS TFG STZ CBS.WD GTN NX VZ LVS CPV QCOM FCAU MGM LEN RAD LEN.B VZA GS UBS AAPL GM INTC LUV CBS VIA F GEC WYNN GSC CBS.A CRUS GSJ ABB S T KHC GNE BRCM GJS ULSGF
IRVINE, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- TRI Pointe Group, Inc. (NYSE:TPH) announced today the addition of three new senior-level executives to its corporate team to support its family of homebuilder brands: Heather Breidenthal as Chief Human Resources Officer, Jeff Lake as Vice President of Architecture and Design, and Sherri Drew as Vice President of Design Studios. The expansion of the team, which is based in the Irvine, Calif.
Lennar Corporation’s (LEN - Free Report) diversified line of home offerings for first-time, move-up and active adult homebuyers, and positive housing market fundamentals are the driving factors for this leading homebuilder in the United States. Additionally, synergies from its recent acquisitions are also encouraging. Recently, this leading homebuilder reported stellar first quarter of fiscal 2018 results wherein earnings as well as revenues surpassed the Zacks Consensus Estimate by 20.
WLH CAA KBH LEN MDC LEN.B LYWMU UNF
2018-04-04 zacks - 1
Lennar Corporation (LEN - Free Report) surpassed earnings as well as revenue expectations in the first quarter of fiscal 2018. The company’s first-quarter adjusted earnings of $1.11 per share surpassed the Zacks Consensus Estimate of 92 cents by 20.7%. The reported figure mainly includes integration costs related to the acquisition of CalAtlantic Group, Inc. and one-time non-cash write down of deferred tax assets due to the reduction in the federal corporate income tax rate.
CAA KBH SIG LEN DHI LEN.B BZH BZMD SIG
2018-04-04 zacks - 1
Lennar Corporation (LEN - Free Report) is one of the leading homebuilders in the United States. With overall housing market recovering at a slow but steady pace, Lennar’s order trends have been improving at a consistent pace. Lennar is performing well on the back of its diverse revenue mix, large land supply, above average order growth and better pricing power. Moreover, Lennar’s ancillary platforms — Rialto, Multi-Family, FivePoint and Financial Services — are evolving and are expected to contribute meaningfully in the near future.
CAA SIG GABC LEN CPST DVN LEN.B TLRD SIG
(Reuters) - U.S. homebuilder Lennar Corp (LEN.N) on Wednesday reported first-quarter revenue above Wall Street targets as it sold more homes at higher prices, indicating robust demand ahead of the crucial spring selling season.
CAA LEN LEN.B
19h - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
19h - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
21h - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to CAA / CalAtlantic Group, Inc. on message board site Silicon Investor.
as of ET